Citations

Clear

3138 citation(s) found for "Smith, AM".

Blood board: A virtual forum for classical hematology education and care improvement
Andrade-Gonzalez, Xavier , Martin, Emma C. St. , Nwachukwu, Nneka , Pritzl, Stephanie , Ruan, Gordon , Shah, Deep , Smith, Caleb , Vijayvargiya, Pooja , Godby, Richard , Story, Charlotte McIlwaine , Marshall, Ariela L. , May, Jori E.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6420-6420

10.1182/blood-2025-6420 Get It

Abstract Introduction: The landscape of classical hematology has undergone substantial evolution over the last decade, marked by new diagnostic tools, nuanced therapeutic strategies, and an expanding understanding of underlying pathophysiology. This increasing complexity often presents unique diagnostic and therapeutic challenges. These challenges are further compounded by workforce shortages in classical hematology marked by educational gaps, geographic limitations, and difficulty accessing prompt specialty care. Unlike the well-established “Tumor Boards” in oncology, a comparable dedicated, widely accessible forum for classical hematology has largely been absent. This gap contributes to potential practice heterogeneity and isolation, especially across dissimilar care settings and geographic regions, impacting the consistent application of evidence-based practices and access to specialized expertise. To address this critical need, the “Blood Board” initiative was created to serve as an informal, virtual resource for discussing classical hematology topics and cases, fostering diverse perspectives, and collaborative problem-solving. Methods: The Blood Board was formally launched in April 2025, operating as a bi-monthly, hour-long virtual meeting conducted via non-recorded videoconferencing. The forum was designed with broad inclusivity in mind, welcoming all healthcare professionals involved in the care of adult patients with classical hematologic disorders, including trainees such as hematology/oncology fellows, academic and community-based hematologists, and any other interested providers. To date, dissemination of this initiative has been by word of mouth and e-mails containing a calendar invitation have been sent to anyone interested in participating (https://forms.gle/doyHNSx1SVFBJZmy8). To facilitate participation from various practice models and geographical locations, the virtual format was prioritized, eliminating barriers of travel and time commitment often associated with traditional in-person conferences. Participation is voluntary, encouraging an open and informal environment for de-identified case presentations, didactic discussions, and expert opinion sharing. Self-reported data on participant demographics (e.g., role, practice setting) and geographical representation have been collected to assess the initiative's reach and impact. Results: To date, sessions have consistently garnered engagement with a median of five participants in attendance at each session. There have been over 20 unique participants representing a broad spectrum of roles including both trainees and practicing hematologists/hematologist-oncologists and drawing from private practice, community-based hospitals, and academic medical centers. Over half of all participants were either in fellowship or within five years of completion of training. The virtual format has successfully overcome geographical limitations, attracting attendees from numerous states including Alabama, Florida, Georgia, Maryland, Minnesota, Missouri, Pennsylvania, South Dakota, and Wisconsin highlighting its broad appeal and potential for knowledge dissemination across a wide professional network. Conclusions: The Blood Board has demonstrated utility and met a previously unaddressed need. Sustained intellectual interest in Blood Board, coupled with a wide geographical and professional reach underscores a critical role for accessible, free, and multidisciplinary collaborative platforms in the evolving field of classical hematology. Similar to Tumor Boards, Blood Board promotes knowledge exchange and evidence-based care, garners expert support for challenging cases, and harmonizes clinical approaches, which we hope may ultimately improve patient care outcomes across diverse settings. Furthermore, this platform facilitates a national classical hematology community to support workforce development. Future goals include expanding dissemination efforts, measuring specific educational benefits, analyzing impacts on patient care, and increasing participant diversity, including recruitment of advanced practice providers and pharmacists.
Twelve month landmark analysis of outcomes of relapsed or refractory large B-cell lymphoma patients achieving prolonged remission with glofitamab or epcoritamab in the real-world outcomes of bispecific T-cell engagers (REALBiTE) multi-center, retrospective
Brooks, Taylor, Nedved, Adrienne, Wang, Yucai, Grover, Natalie, Yang, XI, Karimi, Yasmin, Schwarz, Tenley, Schwede, Matthew, McKenna, Marshall, Tiger, Yun Kyoung, Abdel-Razeq, Nayef, Moustafa, Muhamad Alhaj, Reinert, Catherine, Major, Ajay, Trotier, Daniel, Pophali, Priyanka, Baron, Kelsey, Hu, Boyu, Jones, Sally, Saha, Aditi, Dave, Nikita, Landsburg, Daniel, Sears-Smith, Megan, Ghosh, Nilanjan, Salafian, Kiarash, Ayers, Emily, Sundaram, Suchitra, Brody, Joshua, Gibson, Alyssa, Kline, Justin, Munoz, Javier, Morales, Rodolfo Garza, Khan, Eiraj, Khan, Cyrus, Castillo, Brenda, Smith, Stephen, Chinyengetere, Fadzai, Dave, Sandeep, Niu, Alex, Hernandez-Ilizaliturri, Francisco, Caimi, Paolo, Hill, Brian, Karimi, Yasmin , Karimi, Yasmin H , Brooks, Taylor, Nedved, Adrienne, Wang, Yucai, Grover, Natalie, Yang, XI, Schwarz, Tenley, Schwede, Matthew, McKenna, Marshall, Tiger, Yun Kyoung, Abdel-Razeq, Nayef, Moustafa, Muhamad Alhaj, Reinert, Catherine, Major, Ajay, Trotier, Daniel, Pophali, Priyanka, Baron, Kelsey, Hu, Boyu, Jones, Sally, Saha, Aditi, Dave, Nikita, Landsburg, Daniel, Sears-Smith, Megan, Ghosh, Nilanjan, Salafian, Kiarash, Ayers, Emily, Sundaram, Suchitra, Brody, Joshua, Gibson, Alyssa, Kline, Justin, Munoz, Javier, Morales, Rodolfo Garza, Khan, Eiraj, Khan, Cyrus, Castillo, Brenda, Smith, Stephen, Chinyengetere, Fadzai, Dave, Sandeep, Niu, Alex, Hernandez-Ilizaliturri, Francisco, Caimi, Paolo, Hill, Brian

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 4499-4499

10.1182/blood-2025-4499 Get It

Abstract Introduction: Epcoritamab (epco) and glofitamab (glofit) are bispecific antibodies (BsAbs) approved for the treatment of patients (pts) with relapsed or refractory (r/r) large B-cell lymphomas (LBCLs). Their use is associated with relatively high response rates, with some patients experiencing prolonged remission. It is unclear whether continuous treatment beyond 12 months for pts in remission is beneficial, as continued immunosuppression may result in additional toxicity. We sought to report the outcomes of pts with prolonged remission and survival following BsAb administration. Methods: We performed a multicenter retrospective study including 21 US centers evaluating pts with r/r LBCLs receiving commercially available epco or glofit between 2023 and 2025. Baseline characteristics and outcomes were extracted from medical records. Efficacy and survival outcomes were assessed by site investigators and included overall response rate (ORR), complete and partial response (CR, PR) rates. Pts who responded to BsAbs and had ≥365 days of follow-up from initiation of BsAb treatment were included in the analysis. Results: As of May 15, 2025, a total of 312 pts with r/r LBCLs were treated with BsAbs (epco n=193, glofit n=119) with a median age of 66 years (interquartile range [IQR] 59-73) at BsAb start. Most were male (64.5%), had advanced stage disease (77.4%) and had ECOG performance status of ≤1 (93.3%) at BsAb start. Of 207 pts who had initiated treatment with BsAb ≥12 months prior to data cutoff, we identified 31 pts (15.0%) who had a response to BsAbs (19 epco, 12 glofit) and were alive without progression at 12-months post-BsAb initiation and included them in this landmark analysis. Of the cohort of 19 pts treated with epco, 6 discontinued due to reasons other than disease progression including CAR-T cell therapy (n=2), secondary malignancy (n=2), allogeneic transplant (n=1), or other reasons (n=1). Thirteen of 19 pts received ≥12 months of epco treatment, and, with a median follow-up of 16 months from the start of BsAb, 12 of 13 pts continued receiving epco beyond 12 months with one pt discontinuing after 12 months (observed for an additional 41 days prior to censoring). Of the cohort of 12 pts treated with glofit, 8 pts were observed after completing all planned therapy and 4 patients underwent allogeneic transplant. Among all 31 BsAb-treated patients alive and in remission at 12 months, at the time of data cutoff, 5 pts (12.9%) had progressed (2 previously treated with epco and 3 with glofit). Three of the 4 pts who underwent allogeneic transplant after prior glofit treatment experienced disease relapse. A total of 24 pts (77.4%) were alive at the time of last follow-up, with the causes of death being disease progression (n=1), secondary malignancy (n=1), infection (n=1), and unknown cause (n=4). Conclusions: In this large cohort of r/r LBCL pts treated with BsAbs monotherapy in the standard of care setting, a relatively small proportion of pts (15%) achieve the 12 month PFS landmark. In the absence of robust evidence for what constitutes best practice, different strategies are employed, including continuation of BsAb, observation as well as consolidation with allogeneic transplant or CAR T-cell therapy. Additional follow-up will be reported to help guide clinical decision making regarding the optimal management strategy for this high risk pt population.
Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop
Rutherford, Sarah C. , Ansell, Stephen M. , Armand, Philippe , Leonard, John P. , Smith, Sonali M. , Timmerman, John M. , Zelenetz, Andrew D. , Gutierrez, Meghan, Béguelin, Wendy , Nadel, Bertrand, Pasqualucci, Laura , LaCasce, Ann S. , Rutherford, Sarah C , Smith, Sonali M , Zelenetz, Andrew D , Béguelin, Wendy , Casulo, Carla , Cerhan, James R , Kridel, Robert , Link, Brian K , Maurer, Matthew , Radtke, Andrea J , Luttwak, Efrat , Salles, Gilles A , Pasqualucci, Laura , LaCasce, Ann Steward , Merryman, Reid W. , Nastoupil, Loretta J. , Casulo, Carla , Cerhan, James R. , Green, Michael Richard , Kahl, Brad S. , Link, Brian K. , Maurer, Matthew J. , Luttwak, Efrat , Salles, Gilles , Sehn, Laurie H.

Mayo Clinic

Blood Advances | December 3, 2025 | Volume: 10 | Issue: 5 | Pages: 1591-1602

10.1182/bloodadvances.2025018079 | PMID 41337699 Get It

Abstract Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Although patients with FL have high response rates to therapy, most develop increasingly resistant disease. In addition, transformation into an aggressive lymphoma is associated with unfavorable outcomes. Many novel agents are under investigation, and early clinical data are encouraging. Aligning treatment with the underlying tumor biology and sequencing of therapies remain key clinical challenges. At the Lymphoma Research Foundation’s biannual 2024 Follicular Lymphoma Scientific Workshop, experts convened to discuss the role of chemotherapy in the context of new therapies, the impact of early progression on treatment sequencing, novel end points in clinical trials, disease biology and the tumor microenvironment, and new treatments on the horizon. This report focuses on updates in FL biology, first-line treatment, the role of progression of disease in 24 months, clinical trial design, and redefining cure in FL.
Outcomes of Ventricular Tachycardia Ablation in Cardiac Laminopathy: An Updated Systematic Review and Single‐Arm Meta‐Analysis
Castrichini, Matteo , Félix, Iuri Ferreira , Vizentin, Vanessa Karlinski , Huynh, Trung, Swain, Will H., Siontis, Konstantinos C. , Killu, Ammar M. , Deshmukh, Abhishek , Ackerman, Michael J. , Giudicessi, John, Ferreira Felix, Iuri , Haq, Ikram U , Castrichini, Matteo , Garmany, Ramin , Huynh, Trung, Haq, Ikram U., Swain, Will H., Giudicessi, John R. , Huynh, Trung

Mayo Clinic

Journal of Cardiovascular Electrophysiology | December 3, 2025 | Volume: 37 | Issue: 2 | Pages: 268-274

10.1111/jce.70193 | PMID 41331778 Get It

ABSTRACT Background Ventricular tachycardia (VT) is a life‐threatening arrhythmia frequently observed in structural heart diseases, including LMNA‐related cardiomyopathy, a genetic disorder associated with high risk of sudden cardiac death and progressive systolic dysfunction. While catheter ablation is an established therapeutic option for VT, its efficacy in cardiac laminopathy remains poorly defined. Objectives To synthesize available evidence on the role and outcomes of VT ablation in patients with cardiac laminopathy. Methods A systematic review and single‐arm meta‐analysis was performed in accordance with PRISMA guidelines. PubMed, Embase, and Cochrane databases were searched for studies reporting VT ablation outcomes in LMNA‐related cardiomyopathy. An inverse variance random‐effects model was applied for meta‐analysis of proportions. Results Seven studies (six cohorts, one abstract) comprising 62 patients (mean age 53.2 ± 9.7 years; 85% male; 88% with implantable cardioverter‐defibrillator) were included. An endocardial/endo‐epicardial approach was used in 93% of cases. Acute procedural success was achieved in 37% (95% CI: 14%–63%; I² = 27.4%), and 28% required multiple procedures. Over a median follow‐up of 26 (9–35) months, VT recurrence occurred in 91% (95% CI: 76%–100%; I² = 37.2%). All‐cause mortality was 54% (95% CI: 39%–70%; I² = 28%), predominantly from cardiac causes (51%, 95% CI: 25%–76%; I² = 53%), and 14% (95% CI: 1%–34%; I² = 42%) underwent heart transplantation. Conclusions In LMNA‐related cardiomyopathy, catheter ablation is associated with high VT recurrence, limited long‐term success, and substantial cardiovascular mortality and transplantation rates, underscoring the importance of ICD implantation and the need for alternative strategies, including variant‐specific and molecularly targeted therapies.
Clinical utility of ECAP dosing in a real-world population delivered via EVOKE therapy: the ECAP study
Pope, Jill , Smith, Gregory L. , Goree, Johnathan , Mekhail, Nagy , Levy, Robert M. , Deer, Timothy R. , Vu, Chau , Shah, Jarna R , Costandi, Shrif , Rosen, Steven M., Bromberg, Todd A., Patel, Atish, Latif, Usman , Lad, Shivanand P. , Jameson, Jessica , Calodney, Aaron , Falowski, Steven , Smith, J. Carson , Guirguis, Maged , Boeding, Ronald B., Sprintz, Michael, Antony, Ajay, Patterson, Denis G., Laufer, Andras, Pilitsis, Julie G. , Miller, Nathan , Rosenfeld, David J. , Tate, Jordan L, Raslan, Ahmed M. , Kallewaard, Jan Willem , Leitner, Angela , Hanson, Erin, Soliday, Nicole, Petersen, Erika , Goree, Johnathan A , Mekhail, Nagy A , Costandi, Shrif J , Lam, Christopher M , Hayek, Salim , Hagedorn, Jonathan M , Kallewaard, Jan Willem , Duarte, Rui , Deer, Tim , Shah, Jarna , Rosen, Steven M, Sayed, Dawood , Lam, Christopher , Hayek, Salim M. , Hagedorn, Jonathan M. , Heros, Robert , Miller, Nathan, Tate, Jordan L, Hanson, Erin, Duarte, Rui

Mayo Clinic

Regional Anesthesia & Pain Medicine | December 2, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-107051

10.1136/rapm-2025-107051 | PMID 41330601 Get It

Background The efficacy of EVOKE therapy, a closed-loop spinal cord stimulation (SCS) system, has been demonstrated in a double-blinded randomized controlled trial (RCT). RCT evidence, however, may not be generalizable to clinical practice, while limitations of real-world evidence may affect its validity. The aim of this study was to evaluate the effectiveness of EVOKE therapy in routine clinical practice employing a rigorous data collection approach. Methods The ECAP study was a prospective, multicenter, single-arm, pragmatic study that enrolled SCS candidates with chronic, intractable trunk and/or limb pain in 22 US investigational sites. PROMIS-29 questionnaire and objective neurophysiological metrics were collected, and minimal clinically important differences (MCIDs) were used to characterize baseline dysfunction and response to EVOKE therapy both at trial end and maximal analgesic effect post-implant visit. Pre-specified subgroup analyses were conducted based on diagnosis. Results EVOKE therapy observed included a dose ratio of 1.3 and neural dose accuracy of 2.8 μV. Improvements of >1 MCID were observed for all domains and improvements of ≥2 MCIDs were observed for six of the seven domains. Improvements observed at trial end were maintained or improved at post-implant visit, with statistically significant improvement in holistic MCID (MD 0.2, 95% CI 0.1 to 0.4, p=0.004), and a significantly greater proportion of patients considered holistic MCID responders (p=0.047). Subgroup analysis by diagnosis showed similar outcomes. Conclusions EVOKE therapy was associated with clinically meaningful improvements in a real-world chronic pain population across different subgroups and disease pathologies, with effects observed at trial end reproduced at post-implant visit.
Patient Awareness of Alcohol Consumption and Breast Cancer Risk
Mussallem, Dawn M. , Farkouh, Elizabeth K. , Smith, Taryn , Smith, Taryn L., Farkouh, E K , Wang, Jing

Mayo Clinic

American Journal of Lifestyle Medicine | November 29, 2025 | Volume: 20 | Issue: 3 | Pages: 418-431

10.1177/15598276251401194 | PMID 41328320 Get It

Objective To estimate the proportion of female patients from Mayo Clinic Family Medicine and Community Internal Medicine clinics who are aware of alcohol use as a breast cancer (BC) risk factor. Patients and Methods One thousand women aged 21 to 70 completed a survey collecting information on demographics, medical/family history, frequency and quantity of alcohol consumption, and other health behaviors. Participants were also asked to grade how likely certain factors were to increase lifetime BC risk. Results Most participants (844/990 [85.3%]) identified a family history of BC as a BC risk factor. In contrast, 48.4% (475/982) identified alcohol use as a BC risk factor. The remaining 51.6% (507/982) reported either they were not sure about alcohol consumption as a risk factor (341/982 [34.7%]), believed that there was no association (143/982 [14.6%]), or believed that alcohol consumption decreases the risk of BC (23/982 [2.3%]). In multivariable analyses, factors associated with awareness of alcohol consumption and BC risk included having never been pregnant ( P = 0.048), more education ( P < 0.001), and higher frequency of alcohol consumption in the past 12 months ( P = 0.005). Conclusion Further education of patients and the public is needed to promote awareness of alcohol as a risk factor for BC.
Community-based Multimodal Rehabilitation Improves Function and Performance in Postural Orthostatic Tachycardia Syndrome (POTS)
Rich, Emily , Vas, Asha , Evetts, Cynthia Lee , Kaplan-Smith, Geneva, Goodman, Brent P., Rich, Emily M , Goodman, Brent

Mayo Clinic

NeuroRehabilitation | November 27, 2025 | Volume: 58 | Issue: 1 | Pages: 103-119

10.1177/10538135251395291 | PMID 41308081 Get It

Background Individuals with neurologic impairment, such as brain injury, are more likely to have autonomic dysfunction, including POTS, but often experience a lack of treatment options and access to quality care. Objective Examine the feasibility and outcomes of a group-based multimodal rehabilitation training program. Methods Nineteen females, ages 18–53 (M = 28.6) completed the outpatient training program. The intervention included eight 50-min weekly sessions using an interdisciplinary, multimodal approach, including education, movement, and mindful self-compassion. Participants completed demographic and medical history and assessment for baseline orthostatic intolerance. At pre-training, post-training, and follow-up, participants completed the Modified Fatigue Impact Scale (MFIS), Lower Extremity Functional Scale (LEFS), Rand 36-Item Health Survey 1.0 (RAND-36), Trail Making Test (A and B) (TMT-A, TMT-B), 10-Meter Walk Test (10MWT), and grip strength testing. Results At baseline, participants were significantly below norms in daily function (p < 0.001), grip strength (p ≤ 0.001) gait speed (p < 0.001), fatigue (p < 0.001), and quality of life (p < 0.001). Between pre-training and follow-up, participants showed significant improvement across function in daily life tasks (p < 0.01); grip strength in the dominant (p < 0.01) and non-dominant (p < 0.01) hands; gait speed (p < 0.05); levels of fatigue (p < 0.05); cognitive performance (p < 0.05); and quality of life (p < 0.05). Conclusion Individuals with POTS face functional challenges that can be significantly and objectively improved through multimodal rehabilitation. There is a need for provider education and further research to optimize care and quality of life for individuals with POTS.
Soft Tissue-RADS: An ACR Work-in-Progress Framework for Standardized Reporting of Soft-Tissue Lesions on MRI
Rehman, M. Atiq U, Motamedi, Kambiz , Wu, Jim S. , Samet, Jonathan, Ramachandran, Shyam , Havranek, Madison, Fanburg–Smith, Julie C. , Choi, Edwin, Murphey, Mark D. , Chhabra, Avneesh B. , Garner, Hillary W. , Chalian, Majid , Subhawong, Ty K. , Ahlawat, Shivani , Amini, Behrang , Bajaj, Gitanjali , Samet, Jonathan, Ramachandran, Shyam, Havranek, Madison, Xi, Yin , Choi, Edwin, Morris, Carol D.

Mayo Clinic

American Journal of Roentgenology | November 26, 2025 | Volume: 226 | Issue: 3 | Pages: No page available

10.2214/ajr.25.34013 | PMID 41296918 Get It

Developing Global Gastrointestinal Care Capacity
Bryan, Matthew R , Bensen, Gordon P. , Wipper, Benjamin , Felicien, Shikama, Ingabire, Prosper, Rutaganda, Eric , Smith, Matthew , Laird, Rebecca, Makrauer, Frederick, Rubenberg, Lisa A, Chudy‐Onwugaje, Kenechukwu , Gardner, Timothy B. , Duerksen, Donald R. , Bensen, Steven P., Dusabejambo, Vincent , Dunleavy, Katie A. , Felicien, SHIKAMA, Makrauer, Frederick L., Bensen, Steve P.

Mayo Clinic

Journal of Clinical Gastroenterology | November 26, 2025 | Volume: 60 | Issue: 1 | Pages: 1-9

10.1097/mcg.0000000000002274 | PMID 41295906 Get It

Goals: Describe the establishment and expansion of a global gastrointestinal (GI) partnership and its impact on the advancement of GI care in Rwanda. Background: GI disease disproportionately affects low- and middle-income countries. In Rwanda, governmental and nonprofit efforts have made significant progress in expanding access to health care in the wake of the 1994 genocide; however, specialized care remains largely unrecognized or inaccessible. In response, the Rwanda Ministry of Health established a partnership with an international gastroenterology NGO to address this critical need. Study: We present summative data generated by this partnership. To inform future global GI programs, we provide lessons learned and details about Rwanda’s successful establishment of an in-country, self-sustainable, and locally governed gastroenterology training program. Results: From 2017 to 2023, the partnership expanded the number of clinical sites receiving care from 4 to 11. Total procedural volume increased from 244 to 1069. Most common presenting upper GI symptoms included dyspepsia, reflux, and emesis, while most common lower GI symptoms included hematochezia and constipation. Since 2017, this partnership has increased the number of faculty volunteering in Rwanda (and Rwandan clinicians studying in US academic medical centers), expanded its geographical reach, assisted in the creation of a GI fellowship, and enabled Rwanda to become an East African hub for medical education. Conclusions: Lessons learned across ethical, financial, leadership, cultural, and medical domains from the successful establishment and expansion of an international GI partnership in Rwanda provides invaluable insights to guide development of future models of health care in emerging economies.
Musculoskeletal disorders following hysterectomy with ovarian conservation: a population-based cohort study
Neblett, Michael F. , Rocca, Walter A. , Laughlin-Tommaso, Shannon K., Khan, Zaraq , Ainsworth, Alessandra J. , Smith, Carin Y. , Stewart, Elizabeth A.

Mayo Clinic

Menopause | November 25, 2025 | Volume: 33 | Issue: 4 | Pages: 471-480

10.1097/gme.0000000000002681 | PMID 41288454 Get It

Objectives: To determine the risk of developing de novo carpal tunnel syndrome (CTS), arthritis, or rheumatoid arthritis in women who underwent hysterectomy with bilateral ovarian conservation (H-OC) before reaching spontaneous menopause. Methods: We identified 1,573 women undergoing H-OC for a benign indication at age 18 to 44 years between 1980 and 2002 in Olmsted County, Minnesota. Each woman was age-matched (±1 y) to a referent woman who had not undergone hysterectomy or oophorectomy before the matching date (index date). Diagnostic codes for CTS and arthritis were extracted from the Rochester Epidemiology Project medical records-linkage system through 2019. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models and the two cohorts were balanced for 19 chronic conditions and for several potential confounders present at index date. Results: Over a median 25.8-year follow-up, women undergoing H-OC had an increased risk of developing CTS (HR: 1.33; 95% CI: 1.13-1.56) compared with referent women. The risk was similar in strata by age at H-OC and was higher for women with endometriosis and menstrual disorders indications. Women undergoing H-OC also had an increased risk of developing arthritis (HR: 1.34; 95% CI: 1.23-1.47). The risk was similar in strata by age at H-OC and by indication. Rheumatoid arthritis considered separately was also associated with H-OC (HR: 1.55; 95% CI: 1.05-2.30). Conclusions: H-OC was associated with an increased risk of de novo CTS, arthritis (all types), and rheumatoid arthritis. Further studies are needed to confirm these associations and to explore potential biological mechanisms.